CA2872623A1 - Method for inducing udp-glucuronosyltransferase activity using pterostilbene - Google Patents
Method for inducing udp-glucuronosyltransferase activity using pterostilbene Download PDFInfo
- Publication number
- CA2872623A1 CA2872623A1 CA2872623A CA2872623A CA2872623A1 CA 2872623 A1 CA2872623 A1 CA 2872623A1 CA 2872623 A CA2872623 A CA 2872623A CA 2872623 A CA2872623 A CA 2872623A CA 2872623 A1 CA2872623 A1 CA 2872623A1
- Authority
- CA
- Canada
- Prior art keywords
- pterostilbene
- cancer
- ugt
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010092364 Glucuronosyltransferase Proteins 0.000 title claims abstract description 104
- 102000016354 Glucuronosyltransferase Human genes 0.000 title claims abstract description 103
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 title claims abstract description 94
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 title claims abstract description 93
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000000694 effects Effects 0.000 title claims abstract description 26
- 230000001939 inductive effect Effects 0.000 title description 6
- 238000011282 treatment Methods 0.000 claims abstract description 45
- 230000002062 proliferating effect Effects 0.000 claims abstract description 24
- 230000001413 cellular effect Effects 0.000 claims abstract description 21
- 230000001965 increasing effect Effects 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 230000002829 reductive effect Effects 0.000 claims abstract description 8
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 claims abstract description 4
- ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 claims abstract 3
- 208000009621 actinic keratosis Diseases 0.000 claims description 61
- 230000014509 gene expression Effects 0.000 claims description 50
- 241000282414 Homo sapiens Species 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 201000001441 melanoma Diseases 0.000 claims description 12
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 10
- 201000000849 skin cancer Diseases 0.000 claims description 8
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- -1 pterostilbene compound Chemical class 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 3
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 3
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 208000004649 neutrophil actin dysfunction Diseases 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- ZNHVWPKMFKADKW-LQWMCKPYSA-N 12(S)-HETE Chemical compound CCCCC\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-LQWMCKPYSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 31
- 210000003491 skin Anatomy 0.000 description 29
- 201000008261 skin carcinoma Diseases 0.000 description 28
- 102100031950 Polyunsaturated fatty acid lipoxygenase ALOX15 Human genes 0.000 description 21
- 101710164073 Polyunsaturated fatty acid lipoxygenase ALOX15 Proteins 0.000 description 21
- 210000002752 melanocyte Anatomy 0.000 description 17
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 15
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 15
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 15
- 235000021283 resveratrol Nutrition 0.000 description 15
- 229940016667 resveratrol Drugs 0.000 description 15
- 210000002510 keratinocyte Anatomy 0.000 description 14
- 230000003902 lesion Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 238000003384 imaging method Methods 0.000 description 13
- 239000002417 nutraceutical Substances 0.000 description 13
- 235000021436 nutraceutical agent Nutrition 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000001574 biopsy Methods 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000005855 radiation Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 9
- 210000002615 epidermis Anatomy 0.000 description 9
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 8
- 102100040373 UDP-glucuronosyltransferase 2B17 Human genes 0.000 description 8
- 101710200687 UDP-glucuronosyltransferase 2B17 Proteins 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 229940114079 arachidonic acid Drugs 0.000 description 7
- 235000021342 arachidonic acid Nutrition 0.000 description 7
- 210000000245 forearm Anatomy 0.000 description 7
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- 239000000411 inducer Substances 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 102100029633 UDP-glucuronosyltransferase 2B15 Human genes 0.000 description 6
- 101710200683 UDP-glucuronosyltransferase 2B15 Proteins 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000023611 glucuronidation Effects 0.000 description 6
- 230000037311 normal skin Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- 101000939535 Homo sapiens UDP-glucuronosyltransferase 2B10 Proteins 0.000 description 5
- 102000003820 Lipoxygenases Human genes 0.000 description 5
- 108090000128 Lipoxygenases Proteins 0.000 description 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 5
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 5
- 102100029634 UDP-glucuronosyltransferase 2B10 Human genes 0.000 description 5
- 102100029819 UDP-glucuronosyltransferase 2B7 Human genes 0.000 description 5
- 101710200333 UDP-glucuronosyltransferase 2B7 Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical group N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000003953 foreskin Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 230000008832 photodamage Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 3
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- HDYANYHVCAPMJV-LXQIFKJMSA-N UDP-alpha-D-glucuronic acid Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O HDYANYHVCAPMJV-LXQIFKJMSA-N 0.000 description 3
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000002113 chemopreventative effect Effects 0.000 description 3
- 230000004734 cutaneous carcinogenesis Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 150000002442 hydroxyeicosatetraenoic acids Chemical class 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 239000002676 xenobiotic agent Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 description 2
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 description 2
- CWJSCIWGSUCULS-UHFFFAOYSA-N 2-hydroperoxyicosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCC=CC=CC=CC=C(OO)C(O)=O CWJSCIWGSUCULS-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 2
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 101000640793 Homo sapiens UDP-galactose translocator Proteins 0.000 description 2
- 101000672037 Homo sapiens UDP-glucose:glycoprotein glucosyltransferase 2 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- UQVKZNNCIHJZLS-UHFFFAOYSA-N PhIP Chemical compound C1=C2N(C)C(N)=NC2=NC=C1C1=CC=CC=C1 UQVKZNNCIHJZLS-UHFFFAOYSA-N 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 238000011804 SKH1 hairless mouse Methods 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102100040361 UDP-glucose:glycoprotein glucosyltransferase 2 Human genes 0.000 description 2
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 description 2
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 2
- 102100029151 UDP-glucuronosyltransferase 1A10 Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012627 chemopreventive agent Substances 0.000 description 2
- 229940124443 chemopreventive agent Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000036561 sun exposure Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000002034 xenobiotic effect Effects 0.000 description 2
- 230000031143 xenobiotic glucuronidation Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- SCJLWMXOOYZBTH-BTVQFETGSA-N (2s,3s,4s,5r,6s)-6-[3-[2-[[3-[3-[(2s,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3-oxopropyl]-5-[(z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1h-pyrrol-2-yl]methyl]-5-[(z)-(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-meth Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(=O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@H](O2)C(O)=O)O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(=O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@H](O2)C(O)=O)O)N1 SCJLWMXOOYZBTH-BTVQFETGSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- TYCYGLFFOSNBLU-UHFFFAOYSA-N 12-hydroxyicosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCC(O)CCC=CC=CC=CC=CC(O)=O TYCYGLFFOSNBLU-UHFFFAOYSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 1
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 description 1
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000796941 Homo sapiens Adenosine kinase Proteins 0.000 description 1
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DCVWQAGUQFBCTF-UHFFFAOYSA-N N-hydroxy-PhIP Chemical compound C1=C2N(C)C(NO)=NC2=NC=C1C1=CC=CC=C1 DCVWQAGUQFBCTF-UHFFFAOYSA-N 0.000 description 1
- 102000002247 NADPH Dehydrogenase Human genes 0.000 description 1
- 108010014870 NADPH Dehydrogenase Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102100020847 Protein FosB Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 240000008976 Pterocarpus marsupium Species 0.000 description 1
- 235000010453 Pterocarpus marsupium Nutrition 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091006627 SLC12A9 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000004896 Sulfotransferases Human genes 0.000 description 1
- 108090001033 Sulfotransferases Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 101710148271 UDP-glucose:glycoprotein glucosyltransferase 1 Proteins 0.000 description 1
- 102100040198 UDP-glucuronosyltransferase 1-6 Human genes 0.000 description 1
- 101710105435 UDP-glucuronosyltransferase 1A10 Proteins 0.000 description 1
- 102100029161 UDP-glucuronosyltransferase 1A4 Human genes 0.000 description 1
- 101710205490 UDP-glucuronosyltransferase 1A4 Proteins 0.000 description 1
- 102100029785 UDP-glucuronosyltransferase 2B4 Human genes 0.000 description 1
- 101710200334 UDP-glucuronosyltransferase 2B4 Proteins 0.000 description 1
- 101710008381 UGT1A6 Proteins 0.000 description 1
- 101150008945 UGT2B10 gene Proteins 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 150000001607 bioavailable molecules Chemical class 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000006505 cellular lipid metabolism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 230000001672 cytoproliferative effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100001238 environmental toxicant Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 125000002367 glucuronosyl group Chemical group 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical class OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000012766 histopathologic analysis Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 101150087532 mitF gene Proteins 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 231100000589 photocarcinogenesis Toxicity 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000024295 regulation of fatty acid oxidation Effects 0.000 description 1
- 230000025600 response to UV Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 150000003871 sulfonates Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/466,827 | 2012-05-08 | ||
| US13/466,827 US8841350B2 (en) | 2011-05-11 | 2012-05-08 | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
| PCT/US2012/064993 WO2013169291A2 (en) | 2012-05-08 | 2012-11-14 | Method for inducing udp-glucuronosyltransferase activity using pterostilbene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2872623A1 true CA2872623A1 (en) | 2013-11-14 |
Family
ID=47142275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2872623A Abandoned CA2872623A1 (en) | 2012-05-08 | 2012-11-14 | Method for inducing udp-glucuronosyltransferase activity using pterostilbene |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8841350B2 (forum.php) |
| EP (1) | EP2846785A4 (forum.php) |
| JP (1) | JP2015523963A (forum.php) |
| KR (1) | KR20150027081A (forum.php) |
| CN (1) | CN104768543A (forum.php) |
| AU (1) | AU2012379655B2 (forum.php) |
| BR (1) | BR112014027646A2 (forum.php) |
| CA (1) | CA2872623A1 (forum.php) |
| IN (1) | IN2014DN09990A (forum.php) |
| MX (1) | MX2014013503A (forum.php) |
| WO (1) | WO2013169291A2 (forum.php) |
| ZA (1) | ZA201408893B (forum.php) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170045343A (ko) * | 2014-09-04 | 2017-04-26 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 피부의 장벽 기능의 ｕｖ-유도 상실을 치료하는데 사용하기 위한 국소 프테로스틸벤 조성물 |
| WO2016037007A1 (en) * | 2014-09-04 | 2016-03-10 | The Regents Of The University Of California | Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia |
| WO2016200447A1 (en) | 2015-06-10 | 2016-12-15 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
| US12134956B2 (en) | 2022-10-11 | 2024-11-05 | Halliburton Energy Services, Inc. | Liner hanger system |
| US12398624B2 (en) | 2023-07-11 | 2025-08-26 | Halliburton Energy Services, Inc. | Self-energizing seal for expandable liner hanger |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6623724B2 (en) * | 1996-09-18 | 2003-09-23 | Applied Genetics Incorporated Dermatics | Dermatological compositions and methods |
| US6414037B1 (en) * | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
| DE10161253A1 (de) | 2001-12-13 | 2003-06-26 | Dragoco Gerberding Co Ag | Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren |
| FR2869229B1 (fr) | 2004-04-26 | 2006-08-25 | Sederma Soc Par Actions Simpli | Utilisation d'un inducteur des ugt par voie topique |
| ES2246165B1 (es) | 2004-07-20 | 2006-12-01 | Universitat De Valencia | Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer. |
| US8426369B2 (en) | 2006-12-07 | 2013-04-23 | Rutgers, The State University Of New Jersey | Prevention and treatment of colon cancer |
| US8509879B2 (en) | 2007-11-06 | 2013-08-13 | The Regents Of The University Of California | Apparatus and method for widefield functional imaging (WiFI) using integrated structured illumination and laser speckle imaging |
| US20090175984A1 (en) | 2008-01-08 | 2009-07-09 | David Rubin | Method and compositions for preserving wine |
| US20090324740A1 (en) | 2008-06-13 | 2009-12-31 | Albritton Iv Ford D | Novel nasal spray |
| US20100240767A1 (en) | 2009-03-23 | 2010-09-23 | Muhammed Majeed | Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof |
| ES2798254T3 (es) | 2009-06-22 | 2020-12-10 | Indus Biotech Private Ltd | Proceso para la obtención de pteroestilbeno purificado y métodos de uso del mismo |
| US20110136751A1 (en) | 2009-10-06 | 2011-06-09 | Green Molecular | Use of Polyphenols in the Treatment of Cancer |
| EP2322159A1 (en) | 2009-10-30 | 2011-05-18 | Green Molecular, S.L. | Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic |
| US8415507B2 (en) * | 2010-02-03 | 2013-04-09 | Laurus Labs Private Limited | Pterostilbene cocrystals |
| US8883218B2 (en) * | 2010-03-26 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Anti-cancer nanoparticle compositions and methods of use |
| WO2012103457A2 (en) | 2011-01-28 | 2012-08-02 | University Of Kentucky | Stilbene analogs and methods of treating cancer |
| WO2013051459A1 (ja) * | 2011-10-02 | 2013-04-11 | キユーピー 株式会社 | ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途 |
-
2012
- 2012-05-08 US US13/466,827 patent/US8841350B2/en active Active - Reinstated
- 2012-11-14 JP JP2015511433A patent/JP2015523963A/ja active Pending
- 2012-11-14 WO PCT/US2012/064993 patent/WO2013169291A2/en active Application Filing
- 2012-11-14 EP EP12876092.3A patent/EP2846785A4/en not_active Withdrawn
- 2012-11-14 CN CN201280074486.2A patent/CN104768543A/zh active Pending
- 2012-11-14 IN IN9990DEN2014 patent/IN2014DN09990A/en unknown
- 2012-11-14 CA CA2872623A patent/CA2872623A1/en not_active Abandoned
- 2012-11-14 AU AU2012379655A patent/AU2012379655B2/en not_active Expired - Fee Related
- 2012-11-14 KR KR20147034337A patent/KR20150027081A/ko not_active Withdrawn
- 2012-11-14 MX MX2014013503A patent/MX2014013503A/es unknown
- 2012-11-14 BR BR112014027646A patent/BR112014027646A2/pt not_active IP Right Cessation
-
2014
- 2014-09-22 US US14/493,058 patent/US10039725B2/en active Active - Reinstated
- 2014-12-04 ZA ZA2014/08893A patent/ZA201408893B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10039725B2 (en) | 2018-08-07 |
| EP2846785A4 (en) | 2016-06-15 |
| WO2013169291A3 (en) | 2015-06-18 |
| AU2012379655A1 (en) | 2014-11-20 |
| US20150011650A1 (en) | 2015-01-08 |
| WO2013169291A2 (en) | 2013-11-14 |
| MX2014013503A (es) | 2015-11-13 |
| KR20150027081A (ko) | 2015-03-11 |
| IN2014DN09990A (forum.php) | 2015-08-14 |
| EP2846785A2 (en) | 2015-03-18 |
| US8841350B2 (en) | 2014-09-23 |
| ZA201408893B (en) | 2016-08-31 |
| JP2015523963A (ja) | 2015-08-20 |
| US20120289605A1 (en) | 2012-11-15 |
| AU2012379655B2 (en) | 2018-01-18 |
| BR112014027646A2 (pt) | 2017-06-27 |
| CN104768543A (zh) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Protective effects of sulforaphane on diabetic retinopathy: activation of the Nrf2 pathway and inhibition of NLRP3 inflammasome formation | |
| US10039725B2 (en) | Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene | |
| Mittal et al. | Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway | |
| Marcheggiani et al. | Modulation of Coenzyme Q10 content and oxidative status in human dermal fibroblasts using HMG-CoA reductase inhibitor over a broad range of concentrations. From mitohormesis to mitochondrial dysfunction and accelerated aging | |
| Hsu et al. | Resveratrol increases anti-aging Klotho gene expression via the activating transcription factor 3/c-Jun complex-mediated signaling pathway | |
| Shi et al. | Overexpression of catalase prevents hypertension and tubulointerstitial fibrosis and normalization of renal angiotensin-converting enzyme-2 expression in Akita mice | |
| US20130245110A1 (en) | Use for cannabinoids | |
| Chun-Bin et al. | The main active components of Curcuma zedoaria reduces collagen deposition in human lung fibroblast via autophagy | |
| Wang et al. | Geraniol improves endothelial function by inhibiting NOX-2 derived oxidative stress in high fat diet fed mice | |
| Chen et al. | Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance | |
| Kam et al. | COX-3: Uncertainties and controversies | |
| Otterson et al. | EUK-207 protects human intestinal microvascular endothelial cells (HIMEC) against irradiation-induced apoptosis through the Bcl2 pathway | |
| Canovai et al. | Preventive efficacy of an antioxidant compound on blood retinal barrier breakdown and visual dysfunction in streptozotocin-induced diabetic rats | |
| Moon et al. | Bay 11‐7082, an NF‐κB Inhibitor, Prevents Post‐Inflammatory Hyperpigmentation Through Inhibition of Inflammation and Melanogenesis | |
| Schmidt et al. | Regulation of heme oxygenase-1 expression by dopamine in cultured C6 glioma and primary astrocytes | |
| Kwak et al. | The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKCδ | |
| Grdović et al. | α‐Lipoic Acid Increases Collagen Synthesis and Deposition in Nondiabetic and Diabetic Rat Kidneys | |
| Lương et al. | The roles of vitamin D in seborrhoeic keratosis: possible genetic and cellular signalling mechanisms | |
| Jung et al. | Antidiabetic effect of SN158 through PPARα/γ dual activation in ob/ob mice | |
| Yalçın et al. | Comparative in vitro and in silico evaluation of the toxic effects of metformin and/or ascorbic acid, new treatment options in the treatment of Melasma | |
| Khan et al. | A new indanedione derivative alleviates symptoms of diabetes by modulating RAGE-NF-kappaB pathway in db/db mice | |
| US20070270501A1 (en) | Medicaments for Treating Barrett's Eesophagus | |
| Abdull Razis et al. | Characterization of the temporal induction of hepatic xenobiotic-metabolizing enzymes by glucosinolates and isothiocyanates: Requirement for at least a 6 h exposure to elicit complete induction profile | |
| Singh et al. | A DISCUSSION ON CHEMOPREVENTION OF ORAL CANCER BY SELECTIVE CYCLOOXYGENASE-2 (COX-2) INHIBITORS. | |
| PARKER et al. | ook of A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20181114 |